Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

The effects of the proton pump inhibitor esomeprazole on the bioavailability of regorafenib in patients with a metastatic colorectal cancer (mCRC) or gastrointestinal stromal tumour (GIST).

Next Previous
Search
Trial Profile

The effects of the proton pump inhibitor esomeprazole on the bioavailability of regorafenib in patients with a metastatic colorectal cancer (mCRC) or gastrointestinal stromal tumour (GIST).

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 02 Feb 2019

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Esomeprazole (Primary) ; Regorafenib (Primary)
  • Indications Colorectal cancer; Gastrointestinal stromal tumours
  • Focus Pharmacokinetics
  • Acronyms REGORA

Most Recent Events

  • 20 Dec 2018 Results published in the Clinical Pharmacology and Therapeutics
  • 04 Mar 2018 Status changed from recruiting to completed.
  • 27 Jul 2017 Planned End Date changed from 1 Jun 2017 to 1 Feb 2018.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top